Retruttide Shows Greatest Weight Loss Potential Among GLP-1s
A new systematic review of 26 randomized controlled trials (RCTs) found that retruttide, an experimental drug developed by Eli Lilly and Company, produces the greatest weight loss among glucagon-like peptide 1 (GLP-1) receptor agonists and co-agonists. The study, conducted by researchers at McGill University in Canada, examined commercially available medications in the class and nine … Read more